SCHEMBL19869683

SCHEMBL19869683

Cc1ccc(-c2cn(C)c(=O)c(C)n2)cc1NS(C)(=O)=O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TP53 P04637 4/20 0.45
▸ SMN1; SMN2 Q16637 2/20 0.45
▸ BRD4 O60885 9/20 0.44
▸ MAPT P10636 4/20 0.43
▸ KDM4E B2RXH2 1/20 0.43
▸ NPC1 O15118 1/20 0.43
▸ ALDH1A1 P00352 1/20 0.43
▸ RAB9A P51151 1/20 0.43
▸ CREBBP Q92793 3/20 0.42
▸ CECR2 Q9BXF3 2/20 0.42
▸ BRD9 Q9H8M2 2/20 0.42
▸ TRIM24 O15164 1/20 0.41
▸ BRD1 O95696 1/20 0.41
▸ TAF1 P21675 1/20 0.41
▸ BRD2 P25440 1/20 0.41
▸ SMARCA4 P51532 1/20 0.41
▸ BRPF1 P55201 1/20 0.41
▸ BPTF Q12830 1/20 0.41
▸ BRDT Q58F21 1/20 0.41
▸ ATAD2 Q6PL18 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19857681 0.79 BRD4 (0.66) BRD4CREBBPCECR2BRD9
SCHEMBL19869682 0.77 BRD4 (0.55) TP53SMN1; SMN2BRD4MAPTKDM4E
SCHEMBL29733316 0.77 BRD4 (0.55) BRD4CREBBPCECR2BRD9
SCHEMBL19857602 0.77 BRD4 (0.55) BRD4CREBBPCECR2BRD9
SCHEMBL19869687 0.76 BRD4 (0.72) BRD4KDM4ENPC1ALDH1A1RAB9A
SCHEMBL16652011 0.75 BRD4 (0.66) BRD4BRD9BRDTBRD7
SCHEMBL29848678 0.75 BRD4 (0.66) BRD4BRD9BRDTBRD7
SCHEMBL16649995 0.73 BRD4 (0.67) SMN1; SMN2BRD4MAPTKDM4EALDH1A1
SCHEMBL19857620 0.71 BRD4 (0.50) BRD4BRD9BRD7
SCHEMBL19869867 0.71 BRD4 (0.55) BRD4CREBBPCECR2BRD9BRDT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3265453-B1 NEW PYRIDINONES AND ISOQUINOLINONES AS INHIBITORS OF THE BROMODOMAIN BRD9 BOEHRINGER INGELHEIM INT (DE) 2022-06-29 — — EP disclosed
US-11319318-B2 Pyridinones and isoquinolinones as inhibitors of the bromodomain BRD9 BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2022-05-03 — — US disclosed
US-20180044335-A1 New Pyridinones and Isoquinolinones as Inhibitors of the Bromodomain BRD9 BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2018-02-15 — — US disclosed
US-20180044335-A1 New Pyridinones and Isoquinolinones as Inhibitors of the Bromodomain BRD9 BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2018-02-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180044335-A1 New Pyridinones and Isoquinolinones as Inhibitors of the Bromodomain BRD9 BRD9, BRD1, BRD2 TP53 595/4885SMN1; SMN2 3471/4885BRD4 5/4885
US-11319318-B2 Pyridinones and isoquinolinones as inhibitors of the bromodomain BRD9 BRD9, BRD1, BRD2 TP53 471/4885SMN1; SMN2 3596/4885BRD4 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback